The Myriad Decision — Impact on Entrepreneurship In Diagnostics and Customized Medicines
Yale Biohaven Entrepreneurship Series
Cantor Colburn partner Anne Maxwell, Ph.D., joins a panel discussion of the Myriad decision and its Impact on entrepreneurship In diagnostics and customized medicines at the Yale School of Medicine in New Haven on Tuesday, March 25, from 4-6 PM. To register, click here.
In 2013, the Supreme Court, in Association for Molecular Pathology v. Myriad Genetics, unanimously held that naturally occurring DNA is a product of nature and not patentable, but that synthetically-produced complementary DNA (cDNA) is. This BioHaven seminar has convened a panel of experts from various sectors of the biotech and pharmaceutical industry to discuss the business implications of cases such as Myriad.